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Abstract Neprilysin is a neutral peptidase that cleaves small 
peptide substrates on the amino-side of hydrophobic amino acid 
residues. In the present study, we have used inhibition of non-
mutated and mutated enzymes with dipeptide inhibitors and 
hydrolysis of the substrate [Leu5, Arg6]enkephalin in order to 
evaluate the contribution of the S2' subsite to substrate and 
inhibitor binding. Our results suggest that (1) Arg-102 and Asn-
542 provide major contributions to the interaction of the enzyme 
with the P2' residue of the substrate, (2) the S2' subsite is vast 
and can accommodate bulky side chains, and (3) Arg-102 
restricts access to the S2' subsite to some side chains such as 
arginine. 
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1. Introduction 
Neprilysin (EC 3.4.24.11, NEP, neutral endopeptidase, 
CD 10, CALLA) is a member of the gluzincin subfamily of 
zinc metalloproteases/peptidases [1]. This group of enzymes is 
characterized by the HE.OH active site consensus sequence 
where the histidine residues are two of the zinc ligands and the 
glutamate is involved in the catalytic mechanism. In gluzin-
cins, a glutamic acid residue is the third zinc ligand. The 
primary structure of NEP has been deduced from cDNA se-
quences for the human, rabbit, rat and mouse enzymes, and 
show a high degree of similarity between species [2-5]. NEP is 
a 94-kDa enzyme that is anchored in the plasma membrane 
with a type II topology. Rabbit NEP consists of a short N-
terminal cytoplasmic domain of 27 residues, a 23-residue 
membrane spanning region, and a large ectodomain of 699 
residues. The enzyme also has 5 glycosylation sites and its 
tertiary structure is stabilized by 6 disulfide bridges. NEP is 
distributed in many tissues including kidney and intestinal 
microvilli, the central nervous system, and the immune sys-
tem. It is involved in the extracellular catabolism of short 
bioactive peptides such as the enkephalins and the atrial na-
triuretic peptide. According to their antinociceptive and anti-
hypertensive properties, NEP inhibitors are of great interest 
[6]. 
In peptidases, enzyme-substrate specificity is determined by 
the formation of interactions between enzyme subsites and 
specific residues of the substrate (residues of the substrate 
positioned in N terminus of the cleavage site are referred to 
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as P and interact with the S subsites of the enzyme whereas 
residues on the C-terminal side of the cleavage site are named 
P' and interact with the S' subsites of the peptidase; Fig. 1). 
In the case of NEP, these interactions have been studied es-
sentially with natural and synthetic peptides or inhibitors [7-
11]. It has been shown that NEP displays a preference for a 
hydrophobic residue in the Pi ' position and for a substrate 
containing a free COOH-terminal carboxylate. The S2' subsite 
is also important for the stabilisation of enzyme/substrate in-
teractions. Indeed, mutagenesis studies have indicated that 
NEP Arg-102 forms a salt bridge or a hydrogen bond with 
the carboxyl/carbonyl group of the P2 ' residue, and NEP Asn-
542 establishes a hydrogen bond with the amino side of the 
same residue [12-14]. Furthermore, using synthetic substrates 
Quay et al. [11] suggested that the S2' subsite of NEP prefers 
hydrophobic lateral chains. However, this subsite is known to 
accept charged residues such as arginine in bradykinin. To 
further investigate this NEP subsite preference, we have cre-
ated mutant enzymes carrying the mutations R102M and/or 
N542G. Since these two NEP residues were shown to interact 
with the peptide backbone around the P2 ' residue of the sub-
strate, it was hypothesized that in the mutated enzymes inter-
action in the S2 ' subsite would depend mostly on the nature of 
the P2 ' lateral chain. 
In this report we have used inhibition of single and double 
mutated enzymes with dipeptides and cleavage of [Leu5, 
Arg6]enkephalin to evaluate the interaction of NEP with the 
substrate P2 ' residue. Our results suggest that (1) Arg-102 and 
Asn-542 provide important contributions to the interaction 
with the P2 ' residue of the substrate, (2) the S2 ' subsite is 
vast and can accommodate bulky side chains, and (3) Arg-
102 restricts access to the S2' subsite to some side chains such 
as arginine. 
2. Materials and methods 
2.1. Site-directed mutagenesis, vector construction and transfection of 
COS-1 cells 
All DNA manipulations were performed using described procedures 
[15]. Oligonucleotide-directed mutagenesis was achieved according to 
the method described by Taylor et al. [16], with an M13 subclone 
containing the proper fragment of NEP cDNA. Recombinant M13-
NEP phages carrying the mutations were screened directly by DNA 
sequencing [17], A DNA fragment containing the mutated region was 
isolated from the replicating form of M13-NEP recombinant phage 
and substituted for the equivalent non-mutated fragment in pSVsec-
NEP, a previously described NEP expression vector [18]. The presence 
of the mutations in the expression vectors was confirmed by sequenc-
ing the coding regions of the NEP cDNA by the chain-termination 
method for double-stranded templates using T7 DNA polymerase 
[19]. 
Non-mutated and mutated enzymes were produced by transient 
expression in COS-1 cells [20] using the standard calcium-phosphate 
coprecipitation procedure [21] as previously described [22]. The day 
following transfection, the serum containing medium was changed for 
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'synthetic medium' (modified from Murakami et al. [23]) and de-
scribed by Lemay et al. [18]. After 16 h of incubation, this medium 
was collected, filtrated through a 0.45 urn Millex membrane and con-
centrated (5-fold) on Centricon-30 (Amicon Canada). 
2.2. Enzyme assays and immunoblotting 
The enzymatic activity was determined as described previously [14] 
using 50 nM of the tritiated substrate [tyrosyl-(3,5 3H)](D-Ala2)-Leu5-
enkephalin (50 Ci/mmol) purchased from Research Product Interna-
tional Inc. The km values were determined by the isotopic dilution 
method. Calculations were done using the program ENZFITTER. In 
order to calculate the kcaX values, the amounts of enzyme were quan-
tified by immunoblot analysis using a purified soluble form of rabbit 
NEP as standard [24]. Immunoblotting was performed as previously 
described using monoclonal antibody 18B5 [14]. The inhibitory etfects 
of dipeptides (Sigma Chemical Co.) were determined by serial dilution 
of the inhibitor in enzymatic assays at a substrate concentration of 50 
nM. IC5o values were calculated using the Sigma plot program. 
2.3. Hydrolysis of enkephalins 
Essentially, enzymatic assays were carried out at 37°C in 100 mM 
of MES/NaOH pH 6.5 containing 1 (xM captopril and 100 uM bes-
tatin (inhibitors of angiotensin-converting enzyme and aminopepti-
dase, respectively) using 5 ug of substrate ([Leu6] enkephalin or 
[Leu5, Arg6] enkephalin) in a final volume of 50 ul. Reactions were 
stopped by freezing reaction tubes at —70°C. The reaction mixture 
was then fractionated at room temperature by reverse-phase HPLC 
on a |iBondapak C18 column, 300 X 3.9 mm with a 2-40% gradient of 
acetonitrile in 0.05% trifluoroacetic acid at a flow rate of 1 ml/min. 
The absorbance of substrates and products was monitored at 214 nm. 
Peaks were identified by amino acid compositions. Percentage of hy-
drolysis was calculated by the estimation of peak area of non-hydro-
lysed substrates and YGG and YGGF products. 
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Fig. 1. Schematic representation of substrate interaction with Si' 
and S2' NEP subsites. NEP subsites are represented by grey half-
circles. Substrate peptide backbone is in the centre and residues in-
volved in the substrate binding are numbered. Notice that Arg-102 
establishes a hydrogen bond or a weak salt bridge with the carbon-
yl/carboxyl side of the P2 ' residue and Asn-542 establishes a hydro-
gen bond with the amino side of the P2 ' residue. 
enzymatic parameters similar to those of membrane-bound 
NEP [18]. The soluble form of the enzyme will be referred 
to as NEP throughout this paper. 
3. Results and discussion 
NEP is known to hydrolyse substrates on the amino side of 
hydrophobic amino acid residues [25]. Although this Si' spe-
cificity is relatively well defined, other subsite preferences are 
less obvious. For example, it has been suggested that NEP S2' 
subsite prefers hydrophobic residues [11]. However, it can 
accommodate leucine, methionine, arginine or glycine lateral 
chains with minor differences in substrate specificity [8]. The 
best explanation for this apparent low S2' specificity is that 
the substrate-enzyme interactions occurring with the peptide 
backbone on either side of P2' residue could hide any subsite 
preference. This hypothesis is supported by our previous dem-
onstration that Arg-102 forms a weak salt bridge or a hydro-
gen bond with the carbonyl/carboxyl group of the substrate 
P2' residue, and that Asn-542 forms a hydrogen bond with the 
amide groups of the same residue (see Fig. 1) [13,14]. To 
assess the S2' specificity we have created mutated NEPs in 
which Arg-102 and/or Asn-542 were replaced by Met and 
Gly, respectively. These mutations should prevent any enzyme 
interaction with the carbonyl/carboxyl and amide groups of 
the P2' residue. The mutations were introduced in secNEP, a 
soluble form of NEP that has been shown previously to have 
3.1. Expression of native and mutated secreted NEPs in 
COS-1 cells 
To obtain non-mutated and mutated enzymes, COS-1 cells 
were transfected with either vector pSVsec-NEP encoding the 
wild-type (non-mutated) enzyme [18] or vectors encoding 
R102M, N542G and R102M/N542G mutated enzymes. After 
recovery and concentration of the media, secreted NEPs were 
detected by immunoblotting and the band intensities com-
pared to standard of known amounts by laser densitometer 
(result not shown). This analysis allowed on one hand to 
quantitate the amounts of each enzyme and on the other 
hand to confirm our previous observations that single and 
double mutations did not interfere with the biosynthesis, 
transport and secretion of the peptidases [13,14]. 
3.2. Kinetic parameters of non-mutated and mutated NEPs 
Mutations R102M and N542G affected mainly the km val-
ues of the enzyme (Table 1) as was observed previously when 
these mutations were introduced in the membrane-bound 
form of NEP [13,14]. This observation confirms our previous 
conclusions that NEP active site located in the ectodomain of 
the enzyme functions independently from the rest of the pro-
tein [18]. The 2-fold increase in km value for R102M NEP and 
Table 1 
Kinetic parameters of non-mutated (wt) and mutated NEPs 
WT 
R102M 
N542G 
R102M/N542G 
^m 
(uM) 
109 ±7 b 
240 ±42 
1399 ±329 
2137 ±146 
"-cat 
(min -1) 
1017 ±49 
1257 ±107 
732 ±81 
412 ±27 
ft-cat'^-m 
(min -
9.33 
5.24 
0.523 
0.193 
7uM) 
AAG"d 
(kcal/mol) 
-
0.4 
1.8 
2.5 
a A G = - i ? T In [(kcJkm) muta ted NEP/(fccat/fcm) non-muta ted NEP] . 
bValues are the mean of three different experiments (mean ± S.E.M.) 
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Phe-
Phe-
Phe-
Phe-
Phe-
i 
mm 
mm 
mm 
1 1 1 
111 
PHE 
TRP 
mm 
in 
ili 
WT 
30.2 ±8.5 a 
6.6 ±0.8 
20.0 ±8.9 
20.8 ±1 
15.9 ±2 
3.5 ±1.2 
32.5 ±3 
2560 ±130 
602.0 
R102M 
1000 
328 ±24 
107 ±11 
34.9 ±2.3 
83.2 ±7.4 
5.5 ±0.33 
157 ±21 
582 ±47 
950.0 
N542G 
3000 
541 ±65 
1000 
475 ±52 
255 ±33.4 
78.7 ±9.5 
681 ±96 
2500 b 
1500 
R102M/ 
N542G 
c 
Nl 
1285 ±320 
1000 
597 ±61 
310 ±92 
194 ±3.3 
1286 ±445 
659 ±100 
1500 
aValues are the mean of three different experiments (mean ± S.E.M.) 
bDue to low solubility of dipeptides the IC50 could not be determined precisely 
CNI, Not inhibited. 
Table 2 
Dipeptide inhibitions of non-mutated and mutated NEPs (IC50 |xM) 
the 13-fold increase for N542G NEP correspond to losses of 
binding energy of 0.4 and 1.8 kcal/mol, respectively (Table 1). 
These values are consistent with the loss of a weak salt bridge 
or one hydrogen bond in each mutant [26]. When both muta-
tions were introduced at the same time in the enzyme, we 
observed an additive effect (21-fold) on the km value of 
NEP (Table 1). In contrast, the kC!A value decreased by only 
2.5-fold (Table 1). These results confirm the involvement of 
Arg-102 and Asn-542 in substrate and inhibitor binding but 
indicate that Asn-542 contributes more to the interaction than 
Arg-102. 
3.3. Inhibition of non-mutated and mutated NEPs with 
dipeptides 
To determine NEP S2' preference, we studied the inhibition 
of wild-type or mutated NEPs with dipeptides. These simple 
inhibitors contain a Pi ' phenylalanine, essential for the inter-
action with the Si' hydrophobic pocket of NEP and a variable 
P2' residue (Phe-X). Inhibition of non-mutated NEP with 
these dipeptides suggests that the S2' subsite prefers non-polar 
side chains (Table 2) and does not appear to easily accommo-
date charged (Arg) or polar (Gin) residues. The size of the 
side chain is not an important factor since similar IC50 values 
were obtained for Phe-Trp and Phe-Ala the two best inhib-
itors. Similarly, Phe-Gly and Phe-Tyr showed almost identical 
inhibition potencies. 
When Arg-102 was replaced by Met, we observed a general 
increase in the IC50 values of the inhibitors, confirming the 
role of Arg-102 in substrate/inhibitor binding (Table 2). This 
mutation affected Phe-Gly and Phe-Ala the most whereas di-
peptides with larger side chains in P2' were affected to a lesser 
extent. The IC50 of Phe-Gln did not increase dramatically. 
However, the value was close to 1 mM confirming again 
that the polar side chain of Gin is not well accepted. Interest-
ingly, replacing Arg-102 by Met facilitates the interaction with 
Phe-Arg. Since replacing Arg by Met is an isosteric substitu-
tion, our observation suggests that the positive charge of Arg-
102 interferes with the binding of Phe-Arg to NEP. As for the 
replacement of Arg-102 by Met, substitution of Gly for Asn-
542 resulted in an increase in the IC50 values of the inhibitors. 
This increase was however larger than that observed with 
R102M NEP confirming that Asn-542 contributes more to 
the binding of these dipeptide inhibitors than Arg-102. With 
this mutant, Phe-Trp and Phe-Phe showed the best inhibition. 
Again Phe-Gly and Phe-Ala were the most affected by the 
mutation, and Arg is not well accepted in the P2' of this 
mutated enzyme. When both Arg-102 and Asn-542 were mu-
tated, the increase observed in the IC50 values was larger than 
for the single mutations reflecting the cooperation of Arg-102 
and Asn-542 in NEP substrate/inhibitor binding. With this 
mutant Phe-Gly had no inhibitory effect, and Phe-Trp and 
Phe-Phe were again the inhibitors with the best IC50 values. 
Inhibition of wild-type and mutated enzymes with dipeptide 
inhibitors has emphasized once again the importance of the 
interactions that Arg-102 and Asn-542 establish with the sub-
strate or in this case with the inhibitor peptide backbone. 
Furthermore, our results show that as the interaction between 
the enzyme and the inhibitor peptide backbone is weakened 
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Fig. 2. Hydrolysis of [Leu5, Arg6] enkephalin by non-mutated and 
mutated NEPs. (A) Primary structure of [Leu5, Arg6] enkephalin 
and localisation of the cleavage sites (black arrows). (B) Percentage 
of intact substrate (dark boxes), YGG (stippled boxes) and YGGF 
(open boxes) peptides generated by hydrolysis of [Leu5, Arg6] enke-
phalin with non-mutated and mutated NEPs. Values are the mean 
of at least three different experiments. 
by successive or concomitant mutations of Arg-102 and Asn-
542, the nature of the P2' side chains becomes more important 
for efficient binding. This is best demonstrated by the behav-
iour of Phe-Gly and Phe-Trp. While both inhibitors have 
similar potency with the non-mutated enzyme, R102M/ 
N542G NEP is not inhibited by Phe-Gly at a concentration 
of 10 mM whereas Phe-Trp is still a good inhibitor. 
3.4. Hydrolysis of [Leu5, Arg6]enkephalin 
To confirm our findings, we studied the hydrolysis of [Leu5, 
Arg6]enkephalin. It is already known that NEP cleaves this 
substrate at the Gly3-Phe4 or Phe4-Leu5 bonds (Fig. 2A) with 
no apparent preference for a hydrophobic or a positively 
charged lateral chain in the P2' position [8]. Fig. 2B shows 
that indeed NEP cleaves [Leu5, Arg6]enkephalin at both sites 
generating similar proportions of YGG and YGGF peptides 
(24.3 ±2% and 23.3 ±2%, respectively). NEP mutants also 
hydrolyse the elongated enkephalin at both sites. However, 
the ratio of YGG to YGGF varied for the different mutants 
(Fig. 2B). Both R102M NEP and R102M/N542G NEP pre-
ferred the Phe4-Leu5 bond over the Gly3-Phe4 bond. The 
former in a 4 to 1 ratio and the latter in a 2 to 1 ratio (Fig. 
2B). In the case of N542G NEP, the Gly3-Phe4 bond was 
cleaved preferentially over the Phe4-Leu5 bond in a 2 to 1 
ratio (Fig. 2B). In the same reaction conditions, non-mutated 
NEP, R102M NEP, N542G NEP and R102M/N542G NEP 
cleaved approximately 80%, 60%, 85% and 70%, respectively, 
of [Leu5]enkephalin at the Gly3-Phe4 bond (results not 
shown). 
These results, in agreement with the dipeptide inhibition 
studies, emphasize the role of Arg-102 of NEP in restricting 
access of the S2' subsite to some residues such as arginine: in 
both mutants where Arg-102 was replaced by Met, Arg was 
preferred to Leu in the S2' subsite. This preference for the 
Phe4-Leu5 bond may be explained by a better activity of 
NEP as a dipeptidyl carboxypeptidase than as an endopepti-
dase when both activities are possible [27,9]. In a previous 
study [13] we speculated that Arg-102 was a key feature in 
directing NEP dipeptidyl carboxypeptidase activity. The 
present study suggests that other structural features of NEP 
are also involved. Finally, our studies with dipeptide inhibi-
tors as well as a previous report [11] have suggested that the 
S2' subsite had a preference for a hydrophobic/aromatic side 
chain. This conclusion is not fully supported by the data ob-
tained from the hydrolysis of [Leu5, Arg6]enkephalin. We be-
lieved the data should be interpreted as indicating that the S2' 
subsite is a vast subsite that can accommodate large side 
chains. Stabilization of substrates or inhibitors in this S2' 
subsite is accomplished by non-specific Van der Waals inter-
actions between the side chain and the enzyme. 
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